ALS/MND Natural History Study Data Repository

This is an observational study collecting information from people with Amyotrophic Lateral Sclerosis (ALS) and other motor neuron disorders (MNDs) like Primary Lateral Sclerosis (PLS) or Kennedy Disease. The study is building a data repository to better understand how these conditions progress over time. You would be eligible to participate if you are between 18 and 90 years old and have a diagnosis of ALS or another motor neuron disorder. The study will track your symptoms and how your disease changes over time using tools like the ALS Functional Rating Scale-Revised (ALSFRS-R) and by measuring your breathing capacity (Slow Vital Capacity or SVC). This information will be collected every 3-4 months for up to 5 years.

Study design
This is an observational study collecting data from up to 5000 participants with ALS or other motor neuron disorders.
What's involved
You would have information collected at each routine clinic visit, including demographics, disease history, and specific measures of your condition every 3-4 months for up to 5 years.
Compensation
Not stated in the trial record.
Follow-up
Your survival and disease progression will be tracked every 3-4 months for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05966038

ALS/MND Natural History Study Data Repository

Recruiting
Not specifiedAges 18–90Observational
Massachusetts General Hospital
~5,000 participants
Updated 2026-05-20 on ClinicalTrials.gov

At a glance

Recruiting sites
18 of 18 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
ALS Functional Rating Scale-Revised (ALSFRS-R)
Measured over Every 3-4 months up to 5 years
+2 more outcomes measured
ALS
PLS
MND (Motor Neurone DIsease)
Kennedy Disease
PMA - Progressive Muscular Atrophy
PBP - Progressive Bulbar Palsy
18 sites across 12 states
Pennsylvania3
California2
Michigan2
Israel2
Italy2
Florida1
Illinois1
Massachusetts1
  • Alexander Sherman · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

A clinical diagnosis of El Escorial of suspected, possible, probable, or definite ALS or
Other motor neuron disorders, including but not limited to Spinal-Bulbar Muscular Atrophy (SBMA, Kennedy's disease), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), and Progressive Bulbar Palsy (PBP)

Exclusion

Disease does not meet criteria for any motor neuron disorder
  • ALS Functional Rating Scale-Revised (ALSFRS-R)Every 3-4 months up to 5 years

    The ALS Functional Rating Scale revised is a 12-item rating scale that measures the progression of disability in patients with ALS. The ALSFRS-r assesses patients' levels of self-sufficiency in areas of feeding, grooming, ambulation and communication. The higher the score, the earlier in the disease progression. It consists of 12 questions with a maximum score of 48 points.

  • Slow Vital Capacity (SVC)Every 3-4 months up to 5 years

    Slow vital capacity test normalized to age, sex, and height

  • SurvivalEvery 3-4 months up to 5 years

    Patient survival or survival equivalent (time to ventilator or feeding tube). Survival equivalent is assessed during routine clinical visits, while mortality event may be reported when becomes known to the treating clinician..